cnn semaglutide Dr. Sanjay Gupta answers your questions about new weight loss drugs UCLA director urges caution on

Understanding how BPC-157 compares to other approaches helps inform treatment decisions

The medical term for these treatments is GLP-1 agonists, and they are changing how providers treat Type 2 diabetes and obesity

TIM PIATKOWSKI, PUBLIC HEALTH RESEARCHER, UNIVERSITY OF QUEENSLAND: We don't really know what the human side effects are and so there's just people experimenting and waiting for something to happen

The application technique, frequency of use, combination with other active ingredients and number of sessions must be adapted to the professional assessment of each case and to the aesthetic response observed